search
Back to results

Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis

Primary Purpose

Otosclerosis

Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Acetylcysteine
Placebo (NaCl)
Sponsored by
Karolinska University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Otosclerosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Otosclerosis where surgery is planned
  • Air / bone gap larger than 20 dB
  • Normal middle ear status

Exclusion Criteria:

  • Hypersensitivity to acetylcysteine
  • Deafness on the other ear
  • Stapedotomy previously performed on the ear
  • Pregnancy
  • Asthma

Sites / Locations

  • Karolinska University Hospital Huddinge
  • Karolinska University Hospital, Dept. of Otorhinolaryngology
  • Academic Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Hearing thresholds

Secondary Outcome Measures

Full Information

First Posted
September 4, 2007
Last Updated
September 10, 2013
Sponsor
Karolinska University Hospital
Collaborators
Karolinska Institutet, AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00525551
Brief Title
Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis
Official Title
Acetylcystein Vid Stapedotomi
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska University Hospital
Collaborators
Karolinska Institutet, AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In otosclerosis, one of the tiny bones of the middle ear is unable to move normally. Sounds cannot be transferred to the inner ear and a conductive hearing loss ensues. The disorder is usually treated by an operation where the bone is replaced by a prosthesis. This restores hearing at low sound frequencies. At high frequencies, surgery is less effective. The smaller effect at high frequencies is probably caused by surgically induced inner ear damage. Animal studies have shown that the drug acetylcysteine can protect the inner ear against damage. It is not known whether the drug has similar effects in humans. This study will assess the efficacy of acetylcysteine in patients undergoing surgery for otosclerosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otosclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
152 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Acetylcysteine
Intervention Description
150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
Intervention Type
Drug
Intervention Name(s)
Placebo (NaCl)
Intervention Description
300 mL 0.9% NaCl
Primary Outcome Measure Information:
Title
Hearing thresholds
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Otosclerosis where surgery is planned Air / bone gap larger than 20 dB Normal middle ear status Exclusion Criteria: Hypersensitivity to acetylcysteine Deafness on the other ear Stapedotomy previously performed on the ear Pregnancy Asthma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dan Bagger-Sjoback, M.D.,Ph.D.
Organizational Affiliation
Karolinska University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anders Fridberger, M.D.,Ph.D.
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Karolinska University Hospital Huddinge
City
Huddinge
ZIP/Postal Code
SE-141 86
Country
Sweden
Facility Name
Karolinska University Hospital, Dept. of Otorhinolaryngology
City
Stockholm
ZIP/Postal Code
SE-171 76
Country
Sweden
Facility Name
Academic Hospital
City
Uppsala
ZIP/Postal Code
SE-75185
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
25763866
Citation
Bagger-Sjoback D, Stromback K, Hakizimana P, Plue J, Larsson C, Hultcrantz M, Papatziamos G, Smeds H, Danckwardt-Lilliestrom N, Hellstrom S, Johansson A, Tideholm B, Fridberger A. A randomised, double blind trial of N-Acetylcysteine for hearing protection during stapes surgery. PLoS One. 2015 Mar 12;10(3):e0115657. doi: 10.1371/journal.pone.0115657. eCollection 2015.
Results Reference
derived

Learn more about this trial

Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis

We'll reach out to this number within 24 hrs